Literature DB >> 11706738

Diagnosis and treatment of hyperparathyroidism.

R Marcus1.   

Abstract

There is currently no ideal long-term medical management for HPT. Estrogen remains an excellent option for selected postmenopausal women. Bisphosphonates provide skeletal protection even though hypercalcemia persists. Calcimimetic drugs appear to offer the best promise for future treatment. For patients who need stabilization as a prelude to surgery, intravenous pamidronate may be very useful. Even if effective long-term therapy is developed for HPT, it must be considered with respect to surgery, which, if successful, is relatively inexpensive and curative. Long-term medical follow-up requires close scrutiny on an indefinite basis. Components of such scrutiny will include periodic health history and physical examination, serum calcium and creatinine concentrations, creatinine clearance, 24 hour urinary calcium excretion, and BMD determinations [10]. If specific drug therapy is given, more frequent monitoring for adverse effects would probably the required.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11706738     DOI: 10.1023/a:1026545813468

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  6 in total

Review 1.  Management of acute hypercalcemia.

Authors:  J P Bilezikian
Journal:  N Engl J Med       Date:  1992-04-30       Impact factor: 91.245

2.  Treatment with with oestrogens of primary hyperparathyroidism in post-menopausal women.

Authors:  J C Gallagher; B E Nordin
Journal:  Lancet       Date:  1972-03-04       Impact factor: 79.321

3.  Hypercalcaemia.

Authors:  M J Jamieson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-02

4.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 5.  NIH conference. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement.

Authors: 
Journal:  Ann Intern Med       Date:  1991-04-01       Impact factor: 25.391

6.  A detailed evaluation of oral phosphate therapy in selected patients with primary hyperparathyroidism.

Authors:  A E Broadus; J S Magee; L E Mallette; R L Horst; R Lang; P S Jensen; J M Gertner; R Baron
Journal:  J Clin Endocrinol Metab       Date:  1983-05       Impact factor: 5.958

  6 in total
  1 in total

Review 1.  Emergencies of calcium homeostasis.

Authors:  Jean-Jacques Body; Roger Bouillon
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.